CRIS

0.42709.03%
JB

Jonathan B. Zung

Chief Development Officer

Dr. Jonathan B. Zung, Ph. D., is Member of Advisory Board of OnKai Inc. from 2024. Dr. Zung served as Member of Scientific Advisory Board at Vial Health Technology, Inc. He serves as Business Development Advisor at Concerto Biosciences, Inc. He is Chief Development Officer of Curis, Inc. from May 1, 2023. He serves as the Chief Development Officer at Evelo Biosciences, Inc. since January 2021. He had been Group President of Clinical Development & Commercialization Services for at Covance, Inc., since April 05, 2016 to April 2018. He has been Member of Advisory Board at Saama Technologies, Inc. Dr. Zung joined Evelo from WCG Clinical, where he served as the President of Sponsor and CRO Programs at WIRB-Copernicus Group, Inc. from June 2018 to December 2020. He has vast pharmaceutical development experience and has led and overseen large-scale development projects in oncology, immunology, cardiovascular disease and other major therapeutic areas. From April 2014 to April 2016, he served as Vice President and Head Global Clinical Sciences & Operations at UCB S. A., a biopharmaceutical company. Before joining UCB, he served as Vice President and Head of Global Development Operations at Bristol-Myers Squibb, where he led a organization that managed clinical trials from Phase II through registration. He also held several positions of increasing responsibility at Pfizer Global Research and Development. He served as Director of Clinical Data Interchange Standards Consortium, Inc. since 2015 and also served as its Chairman. He served as a Member of The Florida Institute of Technology Board of Trustees from 2010 to 2016. Dr. Zung received his Ph. D. in Analytical Chemistry from Emory University in Atlanta and has a B.S. in chemistry from the Florida Institute of Technology in Melbourne, Florida.

Positions